Akebia Therapeutics (AKBA) Cash from Operations Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.33 Bn | 87.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 425.00% |
| 10 | Akebia Therapeutics | 340.48 Mn | 177.88 Mn | 41.25 Mn | -56.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.08% |
| Dec 31, 2025 | 797.02% |
| Sep 30, 2025 | 519.79% |
| Jun 30, 2025 | 321.98% |
| Mar 31, 2025 | 30.08% |
| Dec 31, 2024 | -93.50% |
| Sep 30, 2024 | 6.59% |
| Jun 30, 2024 | -377.38% |
| Mar 31, 2024 | -10.80% |
| Dec 31, 2023 | 95.78% |
| Sep 30, 2023 | -121.20% |
| Jun 30, 2023 | 111.84% |
| Mar 31, 2023 | 18.88% |
| Dec 31, 2022 | 12.94% |
| Sep 30, 2022 | 160.08% |
| Jun 30, 2022 | 51.44% |
| Mar 31, 2022 | 69.44% |
| Dec 31, 2021 | -104.04% |
| Sep 30, 2021 | -106.59% |
| Jun 30, 2021 | -269.64% |